HbA1c News and Research

RSS

Short voice recordings could screen patients for type 2 diabetes

Signs of type 2 diabetes can be detected in just a few seconds from the way someone talks, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows.

29 Sep 2026

Continuous glucose monitors show strong survival benefits for type 2 diabetes patients

People with type 2 diabetes (T2D) on basal insulin, starting continuous glucose monitoring (CGM) had a 44% lower risk of dying from any cause after one year compared with those who did not use CGM, with the risk being 35% lower after two years, according to an analysis of patient data being presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

28 Sep 2026

Semaglutide cuts major heart events, but researchers still cannot fully explain why

In adults with overweight or obesity and established cardiovascular disease but no diabetes, semaglutide reduced major adverse cardiovascular events by 20%, while changes in measured cardiovascular risk factors could not fully explain the benefit with certainty. The findings suggest that additional, as-yet unidentified biological pathways may contribute to semaglutide’s cardiovascular protection.

27 Sep 2026

Gut bacteria signature may predict type 2 diabetes risk

Changes in the composition of bacteria in the gut could provide early warning of type 2 diabetes (T2D), new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has found.

27 Sep 2026

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The authors highlight substantial species differences, warning that mouse heart studies may fail to predict responses in human cardiac tissue and that many proposed cardiac effects still require direct testing.

24 Sep 2026

A chemical used in BPA-free products may have a connection to diabetes control

In adults with type 2 diabetes receiving oral glucose-lowering therapy, higher plasma BPS concentrations were associated with higher HbA1c after accounting for demographic factors, medication adherence, and diet, whereas BPA was not associated with HbA1c. The BPS association was modest and no longer statistically significant after further adjustment for BPA, BMI, and physical fitness, supporting the need for larger studies to determine whether reducing exposure could improve glycemic control.

23 Sep 2026

Type 1 diabetes runners can safely complete marathons with careful glucose management

New research to be presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28th – Oct 2nd) shows, with the use of continuous glucose monitoring (CGM) devices people with type 1 diabetes can complete a marathon safely and achieve finishing times similar to runners without diabetes.

18 Sep 2026

CGM reveals glucose patterns linked to cardiometabolic risk in adults without diabetes

Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) are the clinical gold standards for screening for blood sugar levels yet they provide only static snapshots that fail to reflect the highly dynamic and heterogeneous nature of metabolic impairment.

17 Sep 2026

Fermented dairy was linked to lower mortality, but the pattern shifted at higher intakes

Analysis of 37,366 US adults found that fermented dairy consumption was associated with lower all-cause and cardiovascular mortality, with consumers showing adjusted hazards 18% and 20% lower, respectively, than non-consumers. Dose-response analyses indicated that the inverse association was concentrated at intakes below about 150 grams per day, while the observational study could not establish causality.

16 Sep 2026

Scientists tested how much whole grain makes a difference. The answer was not simply “more”

A meta-analysis of 87 randomized trials found that increasing whole-grain intake was associated with improvements in several cardiometabolic risk factors, although many individual changes were small or clinically unimportant. Dose-response analyses suggested that the magnitude of the effects varied by outcome and intake level, with limited evidence at very high intakes.

16 Sep 2026

Tirzepatide vs semaglutide for asthma: the difference was smaller than researchers expected

In a US multicenter electronic health record study, researchers compared tirzepatide with semaglutide in adults with asthma and type 2 diabetes, matching 8,176 patients in each treatment group. Asthma exacerbation risk was similar between treatments, while tirzepatide was associated with a lower likelihood of receiving a short-acting beta-agonist prescription.

14 Sep 2026

Stricter glucose control may affect quality of life in people living with diabetes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows that, in people living with diabetes (type 1 or 2) using data from continuous glucose monitoring (CGM) devices paired with daily quality-of-life ratings, days with more widely fluctuating glucose readings (while still within safe limits) are followed by days with a better quality life compared to days with more stricter control– suggesting the burden of that stricter control could be preventing those individuals with stricter control from enjoying various activities.

11 Sep 2026

Prediabetes linked to substantial burden of mental health conditions

Announcing a new article publication for BIO Integration. Prediabetes has a high prevalence worldwide; however, the prevalence of mental health conditions within the population with prediabetes is not well understood.

10 Sep 2026

Stevia tastes sweet, but does your body react as if sugar is coming?

In a randomized, double-blind crossover study, researchers tested stevia alone and with glucose in adults with normal weight, overweight, or type 2 diabetes to assess acute effects on blood glucose, insulin, gut hormones, appetite, and subsequent food intake. Stevia produced no significant changes in the measured glycemic or hormonal responses compared with water and did not significantly modify responses to glucose, while appetite and subsequent energy intake were also generally unchanged.

8 Sep 2026

Gestational diabetes history linked to earlier development of type 2 diabetes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows that, in women that develop type 2 diabetes (T2D), those who had gestational diabetes (GD) when pregnant are developing T2D on average almost 13 years earlier than those who did not.

3 Sep 2026

The scale told a similar story across three diets. The liver told a different one

In a randomized controlled trial of people with metabolically unhealthy obesity, approximately 10% weight loss improved insulin sensitivity and several cardiometabolic measures across ketogenic, Mediterranean, and very-low-fat plant-forward diets. However, the very-low-carbohydrate ketogenic diet produced larger improvements in hepatic insulin sensitivity and greater reductions in liver fat and several glucose and insulin measures than the higher-carbohydrate diets.

31 Aug 2026

Is there a best day to take GLP-1 drugs? Researchers looked for an answer

A systematic review of 1,000 screened records identified only three eligible studies examining administration timing for semaglutide, and none directly compared different days of the week or assessed tirzepatide timing. The limited evidence suggests flexible dosing may support adherence and tolerability without compromising glycemic control or weight loss, but these findings rely largely on indirect evidence and expert opinion rather than direct comparative trials.

30 Aug 2026

Semaglutide’s heart benefits may partly involve reduced inflammation

A prespecified analysis of 17,604 SELECT participants found that higher baseline hsCRP was associated with greater risks of major cardiovascular events and death in people with overweight or obesity and established cardiovascular disease. Semaglutide produced rapid and sustained reductions in hsCRP, with changes emerging before substantial weight loss, although the study could not establish whether reduced inflammation directly mediated its cardiovascular benefits.

24 Aug 2026

A two-year diet trial challenges the idea that weight loss is the only result that matters

In the two-year DELISH randomized trial, adults with obesity achieved modest, sustained weight loss with either an adapted Mediterranean-style program or a commercial weight loss program. The Mediterranean-style intervention produced greater improvements in self-reported diet quality, while 24-month weight loss did not materially differ between groups.